Clinical Trial VICCHEM1305


Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

Principal Investigator(s)

Jonathan Irish


  • Protocol No. VICCHEM1305
  • Open Date: 04/02/2013
  • Staging: NA
  • Age Group: Adults
  • Scope: Local
  • Objective: To explore signaling and genetic factors that influence early and late responses to therapy in AML
  • Disease Sites: Leukemia
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.